Provides high-purity Lead-212 isotopes for Targeted Alpha Therapies (TAT) using a proprietary portable generator that converts Radium-224 into Lead-212, enabling nuclear radiopharmacies, hospitals, and research institutions to produce their own supply. This technology reduces reliance on external sources, accelerates clinical development, and supports precision oncology treatments by delivering targeted, high-energy radiation directly to cancer cells.
Funding
Funding not disclosed
Founders
Product
Problem
Targeted Alpha Therapies (TAT) require a reliable supply of high-purity Lead-212 isotopes, but access is often limited due to reliance on external sources and logistical challenges. This scarcity can hinder research and development of new radiopharmaceutical therapies, delaying potential breakthroughs in cancer treatment.
Solution
TAG1 Inc. provides a solution to isotope supply challenges with its proprietary Targeted Alpha Generator 1 (TAG1). This portable generator enables nuclear radiopharmacies, large hospital networks, and research institutions to produce their own supply of high-purity Lead-212 isotopes using Radium-224 as its parent isotope. By providing on-site production capabilities, TAG1 reduces dependence on external suppliers, accelerates clinical development timelines, and supports the advancement of precision oncology treatments. The TAG1 generator facilitates the delivery of targeted, high-energy radiation directly to cancer cells while minimizing damage to surrounding healthy tissue, improving treatment outcomes for various types of cancers, including those difficult to treat with traditional methods.
Target Audience
The primary target audience includes nuclear radiopharmacies, hospital networks, biotech companies, and research institutions involved in the development and application of Targeted Alpha Therapies (TAT) and radioligand therapies (RLT).
Features
- Proprietary and portable Targeted Alpha Generator 1 (TAG1) for on-site Lead-212 production
- Radium-224 to Lead-212 conversion technology
- High-purity Lead-212 isotope output suitable for TAT applications
- Scalable production to meet increasing demands for clinical trials and therapeutic use
- Facilitates research and development of novel radiopharmaceutical therapies
- Supports precision medicine approaches by enabling targeted delivery of alpha particles to cancer cells